OIG Allows Cost-Sharing Waiver for Commercially Insured Patients for Lab Test
- January 16, 2026
A laboratory test manufacturer may waive applicable cost sharing for certain commercially insured patients who receive the test because such arrangement would not generate prohibited remuneration under the Anti-Kickback Statute (AKS) or Beneficiary Inducements CMP, the Department of Health and Human Services Office of Inspector General (OIG) said in an advisory opinion posted January 16.
ARTICLE TAGS
You must be logged in to access this content.